The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery

Current Opinion in Urology

Volumn 17, Issue 5, 2007, Pages 358-362

  Merseburger, Axel S ^a   Kuczyk, Markus A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bladder cancer; Cystectomy; Radiation; Therapy; Transurethral resection of bladder tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE;

BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; COOPERATION; COST OF ILLNESS; CYSTECTOMY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MEDICAL SPECIALIST; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TRANSURETHRAL RESECTION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; MUSCLES; NEOPLASM INVASIVENESS; PATIENT SELECTION; PRACTICE GUIDELINES; QUALITY OF LIFE; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 34548314227     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3282c4afa0     Document Type: Review

References (53)

1. Oosterlinck W, Lobel B, Jakse G, et al. Guidelines on bladder cancer. Eur Urol 2002; 41:105-112.
2. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24:3967-3972.
3. Shabsigh A, Bochner BH. Use of nomograms as predictive tools in bladder cancer. World J Urol 2006; 24:489-498.
4. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160:645-659.
5. Milosevic M, Gospodarowicz M, Zietman A, et al. Radiotherapy for bladder cancer. Urology 2007; 69:80-92.
6. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006; 24:5536-5544.
7. Nagele U, Kuczyk M, Anastasiadis AG, et al. Radical cystectomy and orthotopic bladder replacement in females. Eur Urol 2006; 50:249-257.
8. Stenzl A, Holtl L. Orthotopic bladder reconstruction in women - what we have learned over the last decade. Crit Rev Oncol Hematol 2003; 47:147-154.
9. Hart S, Skinner EC, Meyerowitz BE, et al. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. J Urol 1999; 162:77-81.
10. Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987; 138:1162-1163.
11. Whitmore WF Jr, Batata MA, Ghoneim MA, et al. Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol 1977; 118:184-187.
12. Barnes RW, Dick AL, Hadley HL, Johnston OL. Survival following transurethral resection of bladder carcinoma. Cancer Res 1977; 37:2895-2897.
13. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162:74-76.
14. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995; 153:964-973.
15. Malmstrom PU, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996; 155:1903-1906.
16. Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 1988; 139:470-474.
17. Pollack A, Zagars GZ. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 1996; 14:86-95.
18. De Neve W, Lybeert ML, Goor C, et al. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995; 36:183-188.
19. Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995; 31:247-254.
20. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593-1598.
21. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986; 7:299-310.
22. Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 1984; 131:1069-1072.
23. Shearer RJ, Chilvers CF, Bloom HJ, et al. Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br J Urol 1988; 62:558-564.
24. Naslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol 1994; 33:397-402.
25. Shipley WU, Kaufman DS, Heney NM, et al. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur Urol 1998; 33 (Suppl 4):32-34.
26. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 11:2150-2157.
27. Efstathiou JA, Zietman AL, Kaufman DS, et al. Bladder-sparing approaches to invasive disease. World J Urol 2006; 24:517-529.
28. Housset M, Dufour E, Maulard-Durtux C. Concomitant 5-fluouracil cisplatin and bifractionated split course radiation therapy for invasive bladder cancer. Proc Am Soc Clin Oncol 1997; 16:1139A.
29. Sauer R, Birkenhake S, Kuhn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998; 40:121-127.
30. Weiss C, Wolze C, Engehausen DG, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006; 24:2318-2324.
31. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-3071.
32. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001; 58:380-385.
33. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60:62-68.
34. Waehre H, Ous S, Klevmark B, et al. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer 1993; 72:3044-3051.
35. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145:45-50.
36. Brendler CB, Steinberg GD, Marshall FF, et al. Local recurrence and survival following nerve-sparing radical cystoprostatectomy. J Urol 1990; 144:1137-1140.
37. Frazier HA, Robertson JE, Dodge RK, Paulson DF. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993; 71:3993-4001.
38. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21:690-696.
39. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19:666-675.
40. Hautmann RE. Complications and results after cystectomy in male and female patients with locally invasive bladder cancer. Eur Urol 1998; 33 (Suppl 4): 23-24.
41. Fellin G, Graffer U, Bolner A, et al. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A singleinstitution phase II study. Br J Urol 1997; 80:44-49.
42. Hautmann RE, Gschwend JE, De Petriconi RC, et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176:486-492.
43. Yu RJ, Stein JP, Cai J, et al. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 2006; 176:493-499.
44. Kuczyk M, Turkeri L, Hammerer P, Ravery V. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol 2003; 44:57-64.
45. Nagele U, Anastasiadis AG, Merseburger AS, et al. Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer. Expert Rev Anticancer Ther 2006; 6:871-876.
46. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165:1111-1116.
47. Nielsen ME, Shariat SF, Karakiewicz PI, et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 2007; 51:699-708.
48. Dodd PM, McCaffrey JA, Mazumdar M, et al. Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer. Cancer Invest 2000; 18:626-634.
49. Bajorin DF. Paclitaxel in the treatment of advanced urothelial cancer. Oncology (Williston Park) 2000; 14: 43-52, 57; discussion 58, 61-62.
50. Kaufman DS, Winter KA, Shipley WU. Muscle-invading bladder cancer, RTOG Protocol 99-06:Initial report of a phase I/II trial of selective bladder conservation employing TURBT, accelerated irradiation sensitized with cisplatin and gemcitabine chemotherapy. J Clin Oncol 2005; 23: 379A.
51. Hata M, Miyanaga N, Tokuuye K, et al. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys 2006; 64:1371-1379.
52. Buscarini M, Quek ML, Gill P, et al. Molecular prognostic factors in bladder cancer. BJU Int 2005; 95:739-742.
53. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006; 25:2685-2696.